Trials / Sponsors / Qiming Wang
Qiming Wang
Other Government · 2 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non Small Cell Lung Cancer, EGFR Mutation, Leptomeningeal Metastases | Phase 2 | 2025-05-15 |
| Active Not Recruiting | A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases Lung Cancer (NSCLC), Leptomeningeal Cancer | — | 2025-03-01 |